What Should Investors Know About Bristol-Myers Squibb Company (BMY) Stock?

Large-cap health care company Bristol-Myers Squibb Company has moved -0.7% this afternoon, reaching $48.56 per share. In contrast, the average analyst target price for the stock is $63.23.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company is based in the United States. Bristol-Myers Squibb Company currently returns an annual dividend yield of 4.7%.

Make Sure to Consider the Following Before Buying Bristol-Myers Squibb Company:

  • Bristol-Myers Squibb Company has moved -38.0% over the last year.

  • BMY has a forward P/E ratio of 7.2 based on its EPS guidance of 6.7.

  • Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 3.8%.

  • The company has a price to earnings growth (PEG) ratio of -25.92.

  • Its Price to Book (P/B) ratio is 3.41

Bristol-Myers Squibb Company Has Irregular Cash Flows

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 11,850,000 1,130,000 10,720,000 -10.28
2022 13,066,000 1,118,000 11,948,000 -21.57
2021 16,207,000 973,000 15,234,000 14.55
2020 14,052,000 753,000 13,299,000 80.35
2019 8,210,000 836,000 7,374,000 20.59
2018 7,066,000 951,000 6,115,000

Bristol-Myers Squibb Company's free cash flows have a decent average of $10.78 Billion over the last 6 years, but they are highly variable since their coefficient of variability is 283.9%. The compounded average growth rate over this period is 9.8%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.